Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GMP Warning Letter Downward Trend Accelerates; Few Oral Solids Get Cited

Executive Summary

The number of warning letters issued by FDA to pharmaceutical firms for good manufacturing practices fell by half in fiscal 2003

You may also be interested in...



GMP Warning Letter Use Remains Low In FY 2004

FDA's conservative approach to the use of warning letters to support its GMP enforcement strategy continued from fiscal year 2003 into 2004

GMP Warning Letter Use Remains Low In FY 2004

FDA's conservative approach to the use of warning letters to support its GMP enforcement strategy continued from fiscal year 2003 into 2004

Warning Letter “Templates” Likely Part Of GMP Proposal In August

The Center for Drug Evaluation & Research is likely to propose warning letter "templates" as part of its revisions to the Good Manufacturing Practices regulations coming out in August

Related Content

UsernamePublicRestriction

Register

PS043862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel